Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulranumab in chronic low back pain
NCT00973024Phase 2Terminated
- Sponsor
- Johnson & Johnson
- Start
- Sep 2009
- Primary completion
- May 2011
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of fulranumab in chronic low back pain (CLBP), sponsored by Johnson & Johnson. Started Sep 2009; status: terminated.
02
Drugs
fulranumab
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT00973024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00973024.